This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kirkham, L.-A. S. Articles by Mitchell, T. J. Search for Related Content PubMed PubMed Citation Articles by Kirkham, L.-A. S. Articles by Mitchell, T. J.

Construction and Immunological Characterization of a Novel Nontoxic Protective Pneumolysin Mutant for Use in Future Pneumococcal Vaccines

Division of Infection and Immunity, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, United Kingdom,¹ Vaccines Discovery Research, Wyeth, Pearl River, New York²

Received 3 October 2005/ Accepted 19 October 2005

Pneumolysin, the pore-forming toxin produced by Streptococcus pneumoniae, may have an application as an immunogenic carrier protein in future pneumococcal conjugate vaccines. Most of the 90 S. pneumoniae serotypes identified produce pneumolysin; therefore, this protein may confer non-serotype-specific protection against pneumococcal infections such as pneumonia, meningitis, and otitis media. However, as pneumolysin is highly toxic, a nontoxic form of pneumolysin would be a more desirable starting point in terms of vaccine production. Previous pneumolysin mutants have reduced activity but retain residual toxicity. We have found a single amino acid deletion that blocks pore formation, resulting in a form of pneumolysin that is unable to form large oligomeric ring structures. This mutant is nontoxic at concentrations greater than 1,000 times that of the native toxin. We have demonstrated that this mutant is as immunogenic as native pneumolysin without the associated effects such as production of the inflammatory mediators interleukin-6 and cytokine-induced neutrophil chemoattractant KC, damage to lung integrity, and hypothermia in mice. Vaccination with this mutant protects mice from challenge with S. pneumoniae. Incorporation of this mutant pneumolysin into current pneumococcal vaccines may increase their efficacy.

Editor: J. N. Weiser

This article has been cited by other articles:

• Green, S. N., Sanders, M., Moore, Q. C. III, Norcross, E. W., Monds, K. S., Caballero, A. R., McDaniel, L. S., Robinson, S. A., Onwubiko, C., O'Callaghan, R. J., Marquart, M. E. (2008). Protection from Streptococcus pneumoniae Keratitis by Passive Immunization with Pneumolysin Antiserum. IOVS 49: 290-294 [Abstract] [Full Text]  
• Jefferies, J., Nieminen, L., Kirkham, L.-A., Johnston, C., Smith, A., Mitchell, T. J. (2007). Identification of a Secreted Cholesterol-Dependent Cytolysin (Mitilysin) from Streptococcus mitis. J. Bacteriol. 189: 627-632 [Abstract] [Full Text]